EUVIMEDEUVIMED entdecken
Klinische Studie (Phase IV)Open Access · CC BY-NC 4.0

Feasibility of Decentralised Response‐Guided Albuminuria Monitoring to Optimise Empagliflozin and Finerenone Therapy in Type 2 Diabetes and Chronic Kidney Disease

Jelle M Beernink iD, Gozewijn D Laverman, Hiddo J L Heerspink iD

Diabetes, Obesity and Metabolism · 2026

DOI: 10.1111/dom.71147 ↗

Kurz gefasst

Klinische Studie (Phase IV) in der Zeitschrift Diabetes, Obesity and Metabolism, 2026. Verfasst von Jelle M Beernink und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine/Nephrology, Ziekenhuisgroep Twente, Almelo, the Netherlands. Hauptthemen laut MEDLINE: Albuminuria, Benzhydryl Compounds, Diabetes Mellitus, Type 2, Diabetic Nephropathies. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 41 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Boehringer Ingelheim.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aims

To assess the feasibility of a decentralised response‐guided trial and to characterise urinary albumin‐to‐creatinine ratio (UACR) responses to empagliflozin and finerenone in type 2 diabetes and chronic kidney disease (CKD). Materials and Methods Adults with type 2 diabetes, estimated glomerular filtration rate (eGFR) ≥ 25 mL/min/1.73 m 2 , and UACR > 4.5 mg/mmol (> 40 mg/g) were enrolled in a decentralised response‐guided trial. Participants completed study procedures remotely and received empagliflozin 10 mg once daily for 3 weeks. Based on predefined UACR response thresholds during empagliflozin treatment, participants entered a 4‐week second treatment phase with continuation of empagliflozin, add‐on finerenone or substitution with finerenone. Primary outcomes were feasibility measures, including participant‐reported acceptability, sample delivery and completion of home measurements. Exploratory outcomes included changes in UACR.

Results

Eleven participants completed the study (mean [SD] age 69.6 [6.1] years; mean eGFR 61.1 [24.8] mL/min/1.73 m 2 ; median [IQR] UACR 246.9 mg/g [102.8–457.7]). All predefined feasibility criteria were met: urine and capillary blood sample delivery rates were 100% and 98.8%, respectively; home blood pressure and body weight completion rates were 91.3% and 98.6%. During empagliflozin monotherapy, UACR changed by −18.7% overall, after which nine participants (81.8%) initiated empagliflozin–finerenone combination therapy and 2 (18.2%) switched to finerenone monotherapy. UACR was further reduced by 40.1% after finerenone addition and by 34.0% after finerenone substitution, relative to the end of empagliflozin monotherapy. No serious adverse events or hyperkalaemia events were observed during treatment with empagliflozin, finerenone, or their combination.

Conclusions

A decentralised response‐guided trial was feasible and safe, supporting further evaluation of this approach for individualised optimisation of kidney‐protective therapy in type 2 diabetes and CKD. Trial Registration: ClinicalTrials.gov Identifier: NCT06094920.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

AlbuminuriaBenzhydryl CompoundsDiabetes Mellitus, Type 2Diabetic NephropathiesGlucosidesNaphthyridinesRenal Insufficiency, ChronicAgedFemaleHumansMaleMiddle AgedCreatinineDrug Therapy, CombinationFeasibility StudiesGlomerular Filtration RateSodium-Glucose Transporter 2 InhibitorsTreatment Outcome

Stichwörter der Autor:innen

SGLT2 inhibitorantidiabetic drugclinical trialdiabetes complicationsdiabetic nephropathytype 2 diabetes

Substanzen

Benzhydryl CompoundsCreatinineempagliflozinfinerenoneGlucosidesNaphthyridinesSodium-Glucose Transporter 2 Inhibitors

Autor:innen und Institutionen

  • Department of Internal Medicine/Nephrology, Ziekenhuisgroep Twente, Almelo, the Netherlands.
  • Department of Clinical Pharmacy and Pharmacology, University of Groningen, University Medical Center Groningen, Groningen, the Netherlands.
  • Department of Biomedical Signals and Systems, University of Twente, Enschede, the Netherlands.

ORCID-Profile: Jelle M Beernink, Hiddo J L Heerspink

Förderung

  • Boehringer Ingelheim

Zitieren

APA

Beernink, J. M., Laverman, G. D., & Heerspink, H. J. L. (2026). Feasibility of Decentralised Response‐Guided Albuminuria Monitoring to Optimise Empagliflozin and Finerenone Therapy in Type 2 Diabetes and Chronic Kidney Disease. Diabetes, Obesity and Metabolism. https://doi.org/10.1111/dom.71147

Vancouver

Beernink JM, Laverman GD, Heerspink HJL. Feasibility of Decentralised Response‐Guided Albuminuria Monitoring to Optimise Empagliflozin and Finerenone Therapy in Type 2 Diabetes and Chronic Kidney Disease. Diabetes, Obesity and Metabolism. 2026. doi:10.1111/dom.71147

BibTeX
@article{Beernink2026,
  author = {Beernink, Jelle M and Laverman, Gozewijn D and Heerspink, Hiddo J L},
  title = {Feasibility of Decentralised Response‐Guided Albuminuria Monitoring to Optimise Empagliflozin and Finerenone Therapy in Type 2 Diabetes and Chronic Kidney Disease},
  journal = {Diabetes, Obesity and Metabolism},
  year = {2026},
  doi = {10.1111/dom.71147}
}
Kostenlos starten →